Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zostavax Coverage Under Part D Sets Precedent For New Vaccines

Executive Summary

Merck is working to gain CMS support for a web-based billing system that would facilitate Part D coverage for its recently-introduced shingles vaccine Zostavax

You may also be interested in...



Merck Q3: Zostavax Nears Part D Hurdles, Gardasil Sales On Fast Track

Merck will seek to drive continued growth of its shingles vaccine Zostavax through promotional activity and efforts to facilitate reimbursement, the firm said

Merck Q3: Zostavax Nears Part D Hurdles, Gardasil Sales On Fast Track

Merck will seek to drive continued growth of its shingles vaccine Zostavax through promotional activity and efforts to facilitate reimbursement, the firm said

Therapeutic Biologics Approvals Up In 2006, Overall BLA Approvals Steady

Overall 2006 biological license application approvals held steady from 2005 at 10 approvals, but the year saw a significant increase in approvals of therapeutic biologics

Related Content

UsernamePublicRestriction

Register

PS047543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel